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background: Gynaecological laparoscopic surgery outcomes can be compromised by the formation of de novo adhesions. This ran-
domized, double-blind study was designed to assess the efficacy and safety of 4% icodextrin solution (Adeptw) in the reduction of de novo
adhesion incidence compared to lactated Ringer’s solution (LRS).
methods: Patients undergoing laparoscopic surgery for removal of myomas or endometriotic cysts were treated with randomized solution
as an intra-operative irrigant and 1l post-operative instillate. De novo adhesion incidence (number of sites with adhesions), severity and extent
were independently scored at a second-look procedure and the efficacy of the two solutions compared. The effect of surgical covariates on
adhesion formation was also investigated. Initial exploratory analysis of individual anatomical sites of clinical importance was progressed.
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results: Of 498 patients randomized, 330 were evaluable (160 LRS – 75% myomectomy/25% endometriotic cysts; 170 Adept – 79%
myomectomy/21% endometriotic cysts). At study completion, 76.2% LRS and 77.6% Adept had ≥1 de novo adhesion. The mean (SD)
number of de novo adhesions was 2.58 (2.11) for Adept and 2.58 (2.38) for LRS. The treatment effect difference was not significant (P ¼
0.909). Assessment of surgical covariates identified significant influences on the mean number of de novo adhesions regardless of treatment,
including surgery duration (P ¼ 0.048), blood loss in myomectomy patients (P ¼ 0.019), length of uterine incision in myomectomy patients
(P, 0.001) and number of suture knots (P, 0.001). There were 15 adverse events considered treatment-related in the LRS patients
(7.2%) and 18 in the Adept group (8.3%). Of 17 reported serious adverse events (9 LRS; 8 Adept) none were considered treatment-related.
conclusions: The study confirmed the safety of Adept in laparoscopic surgery. The proportion of patients with de novo adhesion for-
mation was considerably higher than previous literature suggested. Overall there was no evidence of a clinical effect but various surgical cov-
ariates including surgery duration, blood loss, number and size of incisions, suturing and number of knots were found to influence de novo
adhesion formation. The study provides direction for future research into adhesion reduction strategies in site specific surgery.
Key words: adhesions / icodextrin / laparoscopy / myomas / endometriotic cysts
Introduction
Adhesion formation is an almost inevitable consequence of abdomino-
pelvic surgery, posing considerable morbidity and mortality risks
for patients and an associated clinical workload and cost burden
(Ellis et al., 1999; Lower et al, 2000; Lower et al., 2004). Despite
the development and implementation of strategies to reduce adhe-
sions, they remain the most frequent complication of abdominopelvic
surgery (DeWilde and Trew, 2007). Adhesiolysis is the only treat-
ment, although adhesions reform in most patients (mean 85%) regard-
less of the method of adhesiolysis used or the type of adhesion being
lysed (Diamond and Freeman, 2001).
Laparoscopy is believed to be less adhesiogenic and causes fewer de
novo adhesions compared with laparotomy. However, although the
number of adhesions forming may be reduced (Nappi et al., 2007),
the comparative risk of adhesion-related complications following open
and laparoscopic gynaecological surgery is similar for most procedures
(Lower et al., 2004; Nappi et al., 2007). Laparoscopy has many advan-
tages over open surgery and is certainly the preferred current operative
approach, especially in women wishing to become pregnant. Many
patients undergoing laparoscopic myomectomy or laparoscopy for
endometriotic cysts do so with an aim to improve their fertility.
However, even adopting the laparoscopic approach, these procedures
are known to be compromised by a significant rate of de novo adhesion
formation, which could have an impact on successful fertility outcomes
for the patient, as well as putting them at risk of other adhesion-related
complications (Nezhat et al., 1991; Redwine, 1991; Canis et al., 1992;
Hasson et al., 1992; Mais et al., 1995; Dubuisson et al., 1998).
Because of the risk of adhesions forming, myomectomy and
removal of endometriotic cysts are procedures where a second-look
laparoscopy may be recommended for patients wishing to retain fer-
tility. Following laparoscopic myomectomy, it would allow for evalu-
ation of the quality of the uterine scar, which may be an important
consideration in patients wishing to become pregnant (Nezhat et al.,
1991; Harris, 1992; Dubuisson et al., 1995; Dubuisson et al., 2000;
Jin et al., 2009) and in patients with endometriotic cysts, it would
allow the opportunity for lysing of any newly formed adnexal adhe-
sions that could compromise fertility or induce pelvic pain.
Adept (4% icodextrin solution) is a non-viscous, iso-osmotic, clear sol-
ution that has been proven safe and effective as an anti-adhesion device
when used as an irrigant fluid during surgery (minimum 100 ml/30 min)
and then at the end of surgery as a 1000 ml post-operative instillate
providing a fluid reservoir in the peritoneal cavity with a prolonged resi-
dence time of up to 4 days (Brown et al., 2007). Adept acts to tempor-
arily separate peritoneal surfaces through the process of hydroflotation,
thereby minimizing tissue apposition during the critical period of fibrin
formation and mesothelial regeneration following surgery, and thus pro-
viding a barrier to adhesion formation.
Adept is approved for use in both open and laparoscopic abdomi-
nopelvic surgery in Europe and is currently the only device approved in
the USA for adhesion prevention in laparoscopy based on demon-
stration of safety and efficacy in a double-blind randomized controlled
trial (RCT) (Brown et al., 2007). The study found that Adept reduced
adhesion reformation after laparoscopic adhesiolysis compared with
patients treated with lactated Ringer’s solution (LRS).
The Gynaecological ENdoscopic EValuation of Adept (GENEVA)
study was performed to assess the efficacy and safety of Adept as
adhesion reduction prophylaxis to reduce de novo adhesions following
initial laparoscopic surgical removal of myomas or endometriotic cysts.
Patients undergoing primary laparoscopic myomectomy have a high
incidence of de novo adhesion formation, particularly where the
myomectomy requires incisions to the posterior wall of the uterus.
Posterior pelvic adhesions also tend to be more dense and severe
with the potential for tethering of adjacent bowel and/or adnexa
(Tulandi et al., 1993; Myomectomy Adhesion Study Group, 1995;
Dubuisson et al., 1998; Takeuchi and Kinoshita., 2002; Takeuchi
et al., 2005; Practice Committee ASRM., 2008).
Materials and Methods
GENEVA was a double-blind, comparative, randomized study with 25
European centres enrolling patients to assess the safety and efficacy of
Adept compared with LRS when used as an intra-operative irrigating
solution (minimum 100 ml/30 min surgery time) and as a 1 l
post-operative instillate for the reduction of de novo adhesion formation
after laparoscopic surgery for myomas or endometriotic cysts. De novo
adhesions were defined as the formation of adhesions at anatomical
locations where there were no adhesions previously.
Investigators in all study centres were experienced in laparoscopic
surgery for removal of myomas and endometriotic cysts. The surgery
was video recorded according to a detailed protocol to enable all assess-
ments to be made through an independent and blinded review of video
recordings.
The study protocol and conduct was directed by an independent steer-
ing panel (see Appendix 1) who were keen to ensure as homologous a
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study population as possible in the design and conduct of the study.
Blinded de novo adhesion incidence and baseline characteristics of random-
ized patients were monitored by a Data and Safety Monitoring Board
(DSMB, see Appendix 1) on an ongoing basis throughout the study to
establish whether or not the observed de novo adhesion incidence rates
were compatible with the assumptions made for study powering. The
study protocol received written approval from the institutional ethics
committee or institutional review board at each study centre.
Participants
Eligibility criteria required patients to be female, aged 18–45 years, and
undergoing primary removal of myomas or endometriotic cysts. All
patients had a negative pregnancy test prior to entering the study and
agreed to use adequate forms of contraception throughout the study.
Patients underwent a planned second-look laparoscopy 4–16 weeks
after the primary procedure. Before completing any study-related pro-
cedures, all patients were required to give their written, signed informed
consent to participate in the study in accordance with the International
Conference of Harmonization Good Clinical Practice Guidelines. Patients
were free to withdraw from the study at any time for any reason.
Pre-operative exclusions included current pregnancy including ectopic
pregnancy; serum glutamic oxaloacetic transaminase, serum glutamic
pyruvic transaminase and/or bilirubin .20% above the upper range of
normal and considered clinically significant by the study site’s principle inves-
tigator; blood urea nitrogen and creatinine .30% above the upper range of
normal and considered clinically significant; concurrent use of systemic cor-
ticosteroids, antineoplastic drugs and/or radiation; GNRH agonist/antag-
onists (except oral contraceptive—combined estrogen/progesterone) in
the 4 weeks prior to study; active pelvic or abdominal infection; known
allergy to starch-based polymers; known or suspected intolerance or hyper-
sensitivity to the study materials (or closely related compounds) or any of
their stated ingredients; prior surgery for endometriotic cysts or myomas;
non-gynaecological surgical procedure planned to be performed during
the laparoscopic procedure; more than four myomas on pre-operative
ultrasound; largest myoma less than two or .8 cm diameter on pre-
operative ultrasound; endometriotic cysts less than three or .7 cm on pre-
operative ultrasound; history of alcohol or other substance abuse within the
last year; use of another investigational agent; or participation in a clinical
trial within the last 30 days prior to study enrolment. At centres in
France, patients with diabetes mellitus were excluded.
Intra-operative exclusions were: clinical evidence of cancer, pregnancy
including ectopic pregnancy, rectovaginal endometriosis, or endometrio-
sis American Fertility Society (AFS) class III or IV (other than endome-
triotic cysts); conversion to laparotomy; unplanned surgery involving
opening of the bowel (excluding appendectomy); extensive pelvic adhe-
sions (AFS adhesion scores moderate or severe) (American Fertility
Society, 1988); use, during the procedure, of any approved or unap-
proved anti-adhesion agent; use of O2 enhanced insufflation; adhesions
that would require lysing during planned myomectomy or planned
endometriotic cyst removal—other than those around the ovarian
fossa, which would need to be lysed prior to cyst removal; endome-
triotic cysts not removed and ovary not left open; suturing the
ovarian capsule; pedunculated cysts; use of glue; or peritoneum
sutured to fascia (with the exception of the trocar port). Post-operative
exclusions were use of drains and post-operative ovarian histology
consistent with a non-endometriotic cyst.
Reasons for withdrawal included: removal of consent; serious adverse
events or other investigator safety concerns; violation of inclusion/exclu-
sion criteria; or pregnancy.
Figure 1 Study schedule.
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Study schedule
The study duration was up to 20 weeks, allowing for the patient to visit the
study site on three occasions: for a screening/baseline visit, on the day of
surgery and finally for follow-up laparoscopy 4–16 weeks after primary
surgery. The study schedule is illustrated in Fig. 1.
Treatments and allocation
Adept (4% icodextrin solution—Baxter Healthcare, Deerfield, IL, USA)
and LRS were presented in identical 1 l infusion bags provided with an
injection port and a connection point for the irrigation set. Each bag
was labelled according to EC Good Manufacturing Practice requirements
for investigational medicinal products. Each bag had an outer wrap that
contained the study code and patient number on an identification label,
along with product expiry date. Double-blinding was possible as both
fluids are clear and odourless solutions with similar viscosities to water
and they were packaged identically.
Each centre was assigned an adequate stock of blinded treatment packs
containing 3 × 1 l blinded bags of Adept or LRS, with additional packs
provided during the study as required.
Treatment was randomized through a 24-h central randomization tele-
phone system, which centres contacted within 24 h prior to visit 2. Patients
were stratified according to their diagnosis of either myomas or endome-
triotic cysts and were randomized in a 1:1 ratio to separate randomization
lists. In the event that the intra-operative criteria were not met after ran-
domization, the treatment pack assigned was not permitted for allocation
to any other patient in the study. The system was administered by the
study Clinical Research Organization.
Surgical technique
In order to mitigate against any potential inter-surgeon variables, surgical
management was standardized as far as possible (see Table I).
Study treatment
Prior to surgery at visit 2, the treatment packs were pre-warmed in a
theatre-warming cabinet and maintained at approximately body tempera-
ture until use. At surgery, following initial video recording, the abdomen
was washed with study solution and this washing/irrigation of the abdomi-
nal cavity was repeated/continued with a minimum of 100 ml of study sol-
ution at intervals of at least once every 30 min. At the end of surgery, after
a final irrigation with a minimum 100 ml followed by reversal of
Trendelenburg position and evacuation of any intraoperative solution, a
final 1000 ml was instilled from a fresh treatment bag. All trocar ports
≥10 mm were double sutured to the fascia to help minimize any leakage.
Intra-operative variables
During surgery, the following were recorded: duration of operation
(defined as time from commencement of insufflation to skin closure); esti-
mated blood loss during surgery (defined as anaesthetist’s/theatre sister’s
estimate of loss); number and length of incisions made during laparoscopic
myomectomy (measured according to local practice using calibrated
instruments, e.g. probe, ruler) and the number of sutures used following
laparoscopic myomectomy (where interrupted suturing of serosa was
undertaken, this was defined as the number of knots).
Video recording
A comprehensive video protocol was established including investigator
training. Video recordings of 23 adhesion sites designated by the modified
AFS (mAFS) (Brown et al., 2007) and the site of surgery were made at first
and second laparoscopy (see Appendix 2). This allowed for independent
blinded video review and scoring of the number, extent and severity of
adhesions at any of the anatomical study sites throughout the abdomino-
pelvic cavity.
At the second-look laparoscopy, the pre-surgery orientation survey of
eight organ sites followed by filming of 23 adhesion scoring sites was
repeated.
Investigators were advised that should any additional surgical interven-
tions be required at the second-look laparoscopy, these should be under-
taken after the filming.
Independent video reviews
Videos were scored by two primary independent reviewers: Prof Ian
Cooke, University of Sheffield, UK and Mr Jonathan Skull, The Royal
Hallamshire Hospital, Sheffield, UK.
Adhesion scoring was undertaken in accordance with a separate proto-
col to ensure minimal inter-observer variability.
Reviewers were blinded to the study treatment assignment (study arm),
subject confidential information and investigator site identifiers. They were
not blinded to the sequence of visits. However, first and second pro-
cedures were scored independently. All efficacy assessments were made
from the independent reviewers’ video scoring of the 23 specified
........................................................................................
Table I Surgical technique.
Standardized technique Local
practice
Myomas and
endometriotic
cysts
Insufflation pressure 10–
15 mmHg
Use of a
humidifier
Use of supplied polydioxanone
(PDS) sutures
Serosal incision
Suture tail lengths ,3 mm Use of pitressin
Suture knots with three throws
Myomas Strip away from underlying
myometrium using grasping
forceps or myoma screw
Close healthy serosa in two
layers using supplied sutures—
PDS 2.0 or 3.0
Close small serosal defects in
one layer
Suturing of deep
tissue and serosa
Interrupted or
continuous
suturing
Endometriotic
cysts
Only uncomplicated unilateral
or bilateral endometriotic cysts
Incise cyst capsule and drain
with the contents aspirated
Strip away capsule from the
normal ovarian tissue
Ovary left open
Arrest any bleeding from the
ovary with bipolar diathermy
where possible
Where bleeding continues use
a haemostatic figure-of-eight
PDS 2.0 suture placed inside
the ovary at the base but the
capsule itself should not be
closed
No suturing outside the ovary
No use of glue
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adhesion sites and the independent reviewers identified any potential
protocol violations.
Efficacy and safety assessment
The incidence (presence or absence), severity (‘filmy’ or ‘dense and vas-
cular’) and extent (‘,1/3’, ‘1/3–2/3’ or ‘.2/3’) of de novo adhesions
were recorded and scored at the site of surgery and at each of the 23 ana-
tomical sites in accordance with the mAFS system (Brown et al., 2007),
allowing calculation of total mAFS and AFS scores, as well as AFS site-
specific scores for each evaluable video.
Posterior and anterior uterus
In order to assess the potential for an adhesion prevention device to
reduce de novo adhesions, an anatomical site that forms sufficient adhe-
sions with the potential to demonstrate treatment differences is required
for evaluation. As the literature identified posterior uterine myomectomies
as having a high incidence of de novo adhesions that typically involve clini-
cally significant sites such as the adnexa and/or bowel (Dubuisson et al.,
1998; Takeuchi and Kinoshita., 2002; Takeuchi et al., 2005), a focused
exploratory analysis was undertaken to assess incidence, severity and
extent of adhesions in patients undergoing myomectomy with incisions
to the posterior and/or or anterior uterus. No allowance was made for
multiplicity.
Safety
Safety was assessed individually and each event/incident classified by body
system and preferred term using MedDRA (Medical Dictionary for Regu-
latory Activities). The number of events and numbers of patients reporting
at least one event were summarized. Clinically significant abnormal values
from laboratory tests were also assessed as adverse events, as were any
clinically significant changes from baseline.
Figure 2 Patient flow illustrating treatment group comparability.
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Statistical analysis
The statistical analysis was based on a predefined statistical analysis plan.
The efficacy analysis was conducted on an evaluable population of patients
with pre-surgery, post-surgery and second-look video assessments who
had no protocol violations. The safety population consisted of all consent-
ing patients who received randomized treatment.
A sample size of 330 evaluable patients (165 per treatment arm) was
estimated to be required to detect a relative risk reduction of 50% (i.e.
an absolute risk reduction of 15% assuming de novo adhesion formation
in 30% of patients for LRS and 15% with Adept), with at least 90%
power. The LRS rate was based on a review of the literature of adhesion
incidence in the absence of treatment with anti-adhesion agents or LRS,
which identified a per-patient de novo adhesion incidence of 35% follow-
ing laparoscopic myomectomy (Dubuisson et al., 1998) and 21% de novo
formation following laparoscopic removal of endometriotic cysts (Canis
et al., 1992).
A patient recruitment ratio of 2:1 was adopted to recruit approximately
220 myomectomy patients and 110 endometriotic cyst patients with an
estimated control adhesion formation rate of 30%. It was assumed that
using LRS as an irrigant and instillate would not influence this rate.
The DSMB reviewed and monitored unblinded safety data. They set a
level for statistical significance of P, 0.001 on the primary end-point for
benefit of Adept relative to LRS, to recommend early termination of the
study. This conservative approach had no impact on the study sample
size requirements. Following an interim, blinded review of data, it
became clear that the prior assumptions on adhesion rates were incorrect.
For this reason, the DSMB recommended to the study steering panel that
for the study to progress, the primary end-point ought to be modified to
correct for a much higher proportion of patients with de novo adhesions
(75.4% myomas, 86.1% endometriotic cysts, 80% for combined treatment
groups) than predicted from the literature (30%). The steering panel
accepted this recommendation and the revised primary end-point was
the total number of incident de novo adhesions for each patient: the
number of evaluable patients required to complete the study was not
amended and the study power did not require changing.
The primary analysis consisted of an analysis of covariance, adjusting for
the randomization stratification variable, to compare the mean patient
total incidence of de novo adhesions between the Adept and LRS
groups, generating an estimate of treatment effect difference with a 95%
confidence interval (CI) and P-value. The methods used for the primary
analysis were then applied to the total mAFS score, for the de novo adhe-
sions and AFS score in the Adept and LRS groups, and repeated for clini-
cally relevant operative subpopulations and anatomical sites.
Analysis of the original primary outcome was based on a logistic
regression model, including the stratification variable and treatment
group, providing an estimated treatment effect as an odds ratio (OR)
with a 95% CI and P-value.
The impact of study covariates and their interaction with treatment on
the primary outcome was investigated. Covariates included volume of irri-
gation solution; surgery duration; blood loss and in myomectomy patients:
number of incisions; incision length and number of knots.
Results
Study recruitment ran from September 2003 to June 2005, with the
last patient completing follow-up in August 2005. The outcomes of
all patients considered for entry into the study are illustrated in Fig. 2.
A total of 501 patients were screened for eligibility, of these 498
were randomized to treatment prior to first laparoscopic surgery,
although one of these patients was subsequently found to have
failed a screening laboratory test. Of those randomized, 72 patients
were excluded from study treatment due to failure to meet pre-
operative or intra-operative exclusion criteria. A total of 426 patients
met all study criteria and were treated with LRS (209) or Adept (217)
at first laparoscopic surgery. These patients constituted the safety
population. A total of 70 patients did not undergo a second-look
laparoscopy. The majority did not because they either expressed a
wish not to be considered for second-look laparoscopic surgery or
did not return for surgery within the stipulated time period. This left
a total of 356 patients who underwent second-look laparoscopy. Of
these, 26 patients were excluded from the evaluable population
either because of video assessment anomalies which prevented appro-
priate adhesion scoring at all sites, or surgery practice deviations. No
patients were withdrawn due to adverse events. A total of 330 were
...................................................................... ......................................................................
.............................................................................................................................................................................................
Table II Demographic characteristics—comparable evaluable population.
LRS Adept
N Mean (SD) Minimum, maximum N Mean (SD) Minimum, maximum
Age (years)
All patients 160 34.2 (5.4) 18.1, 45.2 170 34.8 (5.5) 21.1, 45.8
Myomas 120 35.3 (4.9) 21.1, 45.2 134 35.5 (5.1) 21.1, 45.4
Endometriotic cysts 40 31.0 (5.5) 18.1, 43.2 36 32.0 (6.1) 22.5, 45.8
Weight (kg)
All patients 160 64.5 (11.5) 43.0, 104.0 170 65.1 (11.7) 47.0, 116.0
Myomas 120 65.3 (12.2) 43.0, 104.0 134 66.0 (12.2) 48.5, 116.0
Endometriotic cysts 40 62.0 (8.8) 49.0, 92.0 36 61.9 (9.2) 47.0, 84.5
Height (m)
All patients 160 1.66 (0.06) 1.45, 1.80 170 1.65 (0.06) 1.50, 1.83
Myomas 120 1.66 (0.06) 1.45, 1.80 134 1.65 (0.06) 1.50, 1.83
Endometriotic cysts 40 1.66 (0.06) 1.52, 1.78 36 1.66 (0.06) 1.52, 1.80
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considered as the evaluable population, having been treated with LRS
(160) or Adept (170) at first laparoscopy and having undergone a
second-look laparoscopy which could be scored according to protocol
by the video assessors. The proportion of myomectomy and endome-
triotic cysts patients was approximately balanced between the two
evaluable treatment groups (LRS 75%/25% and Adept 79%/21%).
The two treatment groups were comparable with respect to patient
demographics as detailed in Table II.
Surgery parameters during first laparoscopic surgery and treatment
volumes are summarized by treatment group for the evaluable popu-
lation in Table III.
Patients randomized to the Adept treatment group had fewer adhe-
sions in total prior to surgery, but in a slightly higher proportion of
patients than the LRS group [LRS—425 adhesions, observed in 84
(52.5%) patients; Adept—387 adhesions, observed in 99 (58.2%)
patients]. Surgical necessity required some pre-existing adhesions to
be lysed. This was similar in both groups: LRS—116 adhesions lysed
(28.8% of total pre-existing adhesions) in 40 (23.1%) patients; Adept
110 adhesions lysed (29.1% of total pre-existing adhesions) in 37
(23.5%) of patients. Post-surgery, 65 (40.6%) LRS patients and 76
(44.7%) Adept patients were observed to have at least one remaining
adhesion.
Duration of surgery, blood loss, number of incisions and length of
incisions were comparable for each treatment group and also compar-
able for the myomectomies by treatment group and endometriotic
cysts. Both treatment groups were treated with similar volumes of
study device as an intra-operative irrigant and as an instillate at close
of surgery. There was little difference in follow-up interval between
initial surgery and second-look laparoscopy for both treatment
groups for all patients and for the subpopulations.
The initial primary efficacy parameter for the study was the pro-
portion of patients reporting de novo adhesions at second-look
surgery. At the end of the study, 76.2% of LRS-treated patients and
77.6% of Adept-treated patients were observed to have one or
.............................................................. ..............................................................
.............................................................................................................................................................................................
Table III Initial laparoscopic parameters—comparability of efficacy population.
All patients LRS Adept
N Number (%) of patients with
adhesions
N Number (%) of patients with
adhesions
Adhesions at initial surgery
Prior to surgery 160 84 (52.5) 170 99 (58.2)
Post-surgery 160 65 (40.6) 170 76 (44.7)
N Mean (SD) Minimim, maximum N Mean (SD) Minimim, maximum
Duration of surgery (min) 159 99.9 (43.4) 30.0, 250.0 170 103.4 (46.4) 25.0, 255.0
Blood loss (ml) 153 143.5 (150.0) 5.0, 1000.0 165 123.3 (125.9) 5.0, 800.0
Number of incisions 122 1.48 (0.73) 1.00, 4.00 134 1.75 (1.11) 1.00, 5.0
Length of incisions (mm) 122 57.0 (24.7) 6.0, 155.0 134 61.3 (30.6) 3.0, 185.0
Number of knots 95 4.81 (3.17) 0.00, 16.00 99 5.49 (4.79) 0.00, 26.00
Volume irrigated (ml) 160 1250.7 (699.3) 150.0, 4000.0 170 1351.4 (788.4) 200.0, 4500.0
Volume of instillate (ml) 160 1006.2 (55.7) 1000.0, 1500.0 170 998.9 (15.3) 800.0, 1006.0
Time to second-look laparoscopy (days) 160 59.0 (37.4) 21.0, 356.0 170 56.4 (25.2) 27.0, 203.0
.............................................. ..............................................
.............................................................................................................................................................................................
Table IV Number of de novo adhesions at second look by treatment and by subgroups.
LRS Adept 95% CI P-value
N Mean (SD) Minimum,
maximum
N Mean (SD) Minimum,
maximum
All patients 160 2.58 (2.38) 0, 13 170 2.58 (2.11) 0, 10 0.03 (20.46, 0.51) 0.909
Myomas 120 2.42 (2.27) 0, 13 134 2.49 (2.12) 0, 10 0.07 (20.47, 0.61) 0.804
Posterior myomas 54 2.65 (2.36) 0, 13 52 2.44 (1.78) 0, 7 20.21 (21.01, 0.60) 0.614
Anterior myomas 34 2.21 (2.24) 0, 11 39 2.21 (2.30) 0, 8 0.00 (21.06, 1.06) 0.999
Anterior/posterior myomas 32 2.25 (2.18) 0, 9 43 2.79 (2.33) 0, 10 0.54 (20.51, 1.60) 0.310
Endometriotic cysts 40 3.05 (2.65) 0, 11 36 2.94 (2.10) 0, 7 20.11 (21.21, 1.00) 0.849
Right ovary cysts 10 2.5 (1.78) 0, 5 9 3.78 (2.33) 0, 7 1.28 (20.72, 3.27) 0.194
Left ovary cysts 28 3.14 (2.89) 0, 11 20 2.70 (1.98) 0, 7 20.44 (21.95, 1.06) 0.556
Bilateral cysts 2 4.50 (3.54) 2, 7 7 2.57 (2.15) 0, 6 21.93 (26.47, 2.62) 0.349
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more de novo adhesions. The OR (CI) of 1.11 (0.66, 1.86) was not sig-
nificant (P ¼ 0.693). For myoma and cyst patients, 75.4% and 86.1%,
respectively, had one or more de novo adhesions. Summaries of the
revised primary efficacy parameter, the total number of de novo adhe-
sions at second-look surgery, are presented for all patients, surgery
subgroup and anatomical sites, by treatment in Table IV. The mean
(CI) estimated difference (Adept-LRS) for all patients of 0.028
(20.46, 0.51) was not significant (P ¼ 0.909).
Figure 3 shows the number of de novo adhesions by subgroups of
the study population (both treatments combined), with P-values for
comparisons between increasing levels of each covariate and the
lowest, reference group, as well as P-values indicating the overall
Figure 3 Impact of surgical covariates on mean number of de novo adhesions for overall evaluable patient population.
............................................................................. ........................ ........................
.............................................................................................................................................................................................
Table V Number of de novo adhesions at second look by categorical covariates and by treatment.
Covariate Category Overall LRS Adept
N Mean (SD) Effect estimate (95% CI), P-value N Mean (SD) N Mean (SD)
Duration (min) ,60 40 2.17 (2.19) Reference 21 2.10 (2.34) 19 2.26 (2.08)
60–89 105 2.22 (2.09) 0.08 (20.73, 0.88), 0.850 48 2.48 (2.19) 57 2.00 (1.99)
90–119 77 2.79 (2.43) 0.88 (0.02, 1.73), 0.045 42 3.07 (2.69) 35 2.46 (2.06)
≥120 107 2.95 (2.21) 1.13 (0.30, 1.97), 0.008 48 2.50 (2.28) 59 3.32 (2.10)
Blood loss (ml) ,50 70 2.27 (1.87) Reference 34 2.32 (1.97) 36 2.22 (1.81)
50–99 71 2.31 (1.97) 0.10 (20.64, 0.85), 0.787 29 2.79 (2.13) 42 1.98 (1.80)
100–199 94 2.65 (2.37) 0.47 (20.23, 1.17), 0.185 44 2.59 (2.47) 50 2.70 (2.30)
≥200 83 3.01 (2.59) 0.86 (0.14, 1.59), 0.019 46 2.70 (2.83) 37 3.41 (2.23)
Number of incisions 1 161 2.42 (2.16) Reference 79 2.54 (2.35) 82 2.29 (1.97)
≥2 95 2.46 (2.17) 0.05 (20.51, 0.60), 0.872 43 2.19 (2.07) 52 2.69 (2.24)
Length of incisions (mm) ,50 96 1.70 (1.62) Reference 47 1.89 (1.75) 49 1.51 (1.47)
≥50 160 2.88 (2.32) 1.18 (0.65, 1.71), ,0.001 75 2.75 (2.47) 85 2.99 (2.19)
Number of knots 1–3 55 2.22 (1.89) Reference 26 1.85 (1.67) 29 2.55 (2.05)
4–5 84 1.75 (1.63) 20.28 (21.07, 0.52), 0.495 45 1.87 (1.82) 39 1.62 (1.39)
≥6 55 3.35 (2.76) 1.31 (0.46, 2.16), 0.003 24 3.58 (2.89) 31 3.16 (2.68)
Volume irrigated (ml) ,1000 88 1.84 (1.75) Reference 45 1.71 (1.58) 43 1.98 (1.92)
1000–1999 141 2.67 (2.11) 0.77 (0.18, 1.37), 0.011 68 2.53 (2.18) 73 2.79 (2.05)
≥2000 101 3.10 (2.62) 1.19 (0.55, 1.83), ,0.001 47 3.47 (2.95) 54 2.78 (2.28)
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significance of each covariate. It illustrates that there is an increasing
number of de novo adhesions with longer duration of surgery (P ¼
0.048), with approximately 3 de novo adhesions per patient for
those in surgery for over 2 h. Overall, blood loss was not found to
be significantly associated with de novo adhesion incidence (P ¼
0.14), though there were signs of a trend (linear effect of blood
loss, P ¼ 0.058), with patients losing in excess of 200 ml developing
a higher number of adhesions than those with ,50 ml blood loss
during surgery (P ¼ 0.019) (Fig. 3). In myomectomy patients, the
overall association reached statistical significance (P ¼ 0.019).
While the number of incisions made during surgery was not found
to be associated with the number of de novo adhesions, the total
length of incisions did appear to be an important factor (P, 0.001).
Also, the number of knots used at myomectomy or endometriotic
cyst surgery sites showed an association with the numbers of de
novo adhesions (P, 0.001), though the effect was not linear, with a
marked increase when six or more knots were used.
Although no treatment effects were found in the population as a
whole, several covariate effects were evident (Table V). These were
also tested for evidence of differences between treatment groups
according to levels of each covariate (i.e. treatment-by-covariate inter-
action). However none of the covariates studied showed a significant
interaction with treatment on the number of de novo adhesions.
Secondary efficacy parameters, including total mAFS score and AFS
are presented by treatment in Table VI together with details for pos-
terior myomectomy. In patients undergoing posterior myomectomy
and where de novo adhesions were observed, the AFS scores for indi-
vidual posterior adhesion scoring sites were examined. The mean de
novo adhesion score was reduced by 46% in Adept patients compared
with LRS at the posterior uterus (AFS site score LRS 5.04: Adept 2.71:
P ¼ 0.007). This reduction in adhesion burden was supported by
similar trends at other adjacent sites where the score of de novo
adhesion burden was lower.
Treatment-related adverse events reported for the safety popu-
lation are summarized in Table VII. The number (%) of patients report-
ing one or more such events was 15 (7.2%) with LRS and 18 (8.3%)
with Adept. Post-procedural pain was the only event reported in
≥2% of patients in both treatment groups. There were 17 adverse
events reported (9 following LRS and 8 following Adept, Table VIII),
which were designated serious due to a requirement for prolonged
hospitalization and/or surgery.
................................................ ................................................
.............................................................................................................................................................................................
Table VI De novo adhesion scoring at second-look laparoscopy.
LRS Adept Adept-LRS (95% CI),
P-value
N Mean (SD) Minimum,
maximum
N Mean (SD) Minimum,
maximum
All patients
Total mAFS (23 sites) 153 8.42 (11.80) 0, 82 159 8.13 (12.37) 0, 71 20.15 (22.84, 2.54), 0.911
AFS score (adnexal sites only) 158 0.78 (2.32) 0, 16 164 0.61 (3.00) 0, 32 20.12 (20.70, 0.46), 0.690
Posterior myomectomy
Total mAFS (23 sites) 51 9.31 (13.44) 0, 66 48 6.73 (9.81) 0, 58 22.58 (27.30, 2.13), 0.280
AFS score (adnexal sites only) 53 0.38 (1.72) 0, 12 48 0.10 (0.42) 0, 2 20.27 (20.78, 0.23), 0.288
AFS site-specific scores
Posterior uterus 27 5.04 (4.13) 1, 16 31 2.71 (2.04) 1, 8 22.33 (24.01, 20.65), 0.007
Rectosigmoid 22 5.18 (3.75) 1, 16 15 3.20 (2.81) 1, 8 21.98 (24.30, 0.33), 0.091
Omentum 10 2.80 (1.55) 1, 4 9 2.33 (1.58) 1, 4 20.47 (21.98, 1.05), 0.525
Anterior uterus 6 4.17 (2.23) 1, 8 6 3.83 (3.43) 1, 8 20.33 (24.05, 3.39), 0.846
Cul-de-sac (posterior) 5 3.00 (3.08) 1, 8 6 1.00 (0.00) 1, 1 22.00 (24.81, 0.81), 0.142
Small bowel 0 – (–) –, – 1 4.00 (–) 4, 4 N/A
All patients, posterior myomectomy subgroup and posterior scoring sites, by treatment group.
........................................................................................
Table VII Adverse events by treatment group.
LRS Adept
Number of patients (safety population) 209 217
Number (%) of patients reporting an
adverse event
72 (34.4) 71 (32.7)
Number (%) of patients reporting a
treatment-related adverse event
15 (7.2) 18 (8.3)
Treatment-related adverse events
(.1 incidence in study)
Post-procedural pain 7 (3.3) 6 (2.8)
Nausea 3 (1.4) 4 (1.8)
Pain non-specific 2 (1.0) 3 (1.4)
Abdominal pain non-specific 2 (1.0) 0 (0.0)
Vomiting non-specific 1 (0.5) 1 (0.5)
Wound infection 1 (0.5) 1 (0.5)
Nausea post-operative 2 (1.0) 0 (0.0)
Headache 1 (0.5) 1 (0.5)
Urinary retention 2 (1.0) 0 (0.0)
Vulval/genital oedema 0 (0.0) 4 (1.8)
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None of these serious adverse events were deemed to be
treatment related. There were no significant differences in laboratory
investigations. No patients died in the study.
Discussion
This was the first double-blind, randomized and controlled study of an
anti-adhesion agent specifically investigating reduction of de novo adhe-
sions in laparoscopic surgery. Most studies of anti-adhesion agents
compare them with surgical technique alone. Importantly, this study
compared Adept with LRS, which has been used as a crystalloid for
irrigation and hydroflotation. The similarity of the two fluids enabled
double-blinding. The study also included blinded and independent
video review with comprehensive adhesion scoring of sites throughout
the abdominopelvic cavity.
During the GENEVA study, the proportion of patients with de novo
adhesion formation following laparoscopic myomectomy (75.4%) and
ovarian cystectomy (86.1%) was considerable and higher than
expected from the literature. On the advice of the DSMB, to enable
the study to progress, the study steering panel changed the primary
end-point to the total number of de novo adhesions for each patient.
The study is distinct from previous research with Adept and with
many other anti-adhesion agents, which focused largely on the refor-
mation of adhesions following surgery with adhesiolysis. The study
sought to focus on de novo adhesion formation. However, 55% of
patients had pre-existing adhesions and to enable surgery to be under-
taken some pre-existing adhesions had to be lysed in 25% of
patients. Adhesions which reformed at these sites of lysis were not
counted within the study analyses. However, it is recognized that
the lysis process may have influenced the observed adhesion
incidence.
We questioned if the reasons for the high number of adhesions
reported reflected differences in the specificity and sensitivity of this
study. The adhesion measures employed in the study, included
scoring throughout the abdominopelvic cavity. Canis et al assessed
adnexal adhesions alone (Canis et al., 1992) and Dubuisson, while
examining adhesions at other sites, including the uterine scar and
pouch of Douglas, appeared to focus on sites adherent to the
uterus and the adnexa (Dubuisson et al., 1998). The GENEVA study
employed more sensitive measures and quantifiable scores of adhe-
sions, including systematic video reading of 23 sites plus the site of
surgery, independent video assessment and robust scoring compared
with the evidence base.
The study was sensitive enough to demonstrate that factors such as
surgery duration, blood loss, suture knots and length of incision influ-
enced de novo adhesion formation. The wide variations in these factors
may have contributed to poor sensitivity to detect changes in the
number of de novo adhesions between treatments.
While the study provided further confirmation of the safety of
Adept in routine surgery, it did not show significant differences
between Adept and LRS in terms of the mean number of de novo
adhesions. Exploratory analysis of the posterior uterus was under-
taken as it was considered clinically valid given it is the most adhesio-
genic of the three sites of myomectomy. Scoring of de novo adhesions
at the posterior uterus following removal of a posterior uterine
myoma, identified a benefit with Adept over LRS.
A possible reason for limited treatment differences may be
explained by some anti-adhesion effect with LRS. This was reported
in the PAMELA study (Brown et al., 2007), although in this study
Adept was shown to reduce adhesion reformation significantly more
than LRS. Conversely, a meta-analysis of the effects of crystalloid sol-
utions on abdominopelvic adhesion development reported that they
did not increase adhesion-free outcomes, possibly because of rapid
absorption of the limited volumes used (Wiseman et al., 1998). The
higher volumes of LRS used in the PAMELA (Brown et al., 2007)
and GENEVA studies and meticulous irrigation throughout surgery
may have had a beneficial impact.
It was clear from the independent video-review process and the
numbers of re-reviews of videos required that this was both a difficult
patient group to study and that the independent review process, while
robust was not without problems in the reading and scoring of adhe-
sions throughout the abdominopelvic cavity.
Most surgeons do not have the opportunity to undertake second-
look therapeutic laparoscopies. In addition, many surgeons do not
have the opportunity to see others operating and thus do not see
differences in techniques that they may then consider adopting to
improve outcomes. The high number of adhesions seen in the
study highlights the potential for onward clinical problems due to
de novo adhesion formation. Adhesions were observed most com-
monly at the posterior uterus and rectosigmoid and although
neither treatment reduced the number of adhesions at these sites,
for those adhesions that were found, the extent and severity (as
measured by AFS scores for individual anatomical sites) was lower
in the Adept group, reaching nominal statistical significance at the
posterior uterus.
The study indicates that the duration of surgery, size of incisions,
suturing and number of knots, and blood loss are all factors influencing
adhesion outcomes. Although the study did not assess the
............................................... .....................................
........................................................................................
Table VIII Adverse events designated serious due to a
requirement for prolonged hospitalization and/or
surgery.
LRS Adept
Event designated serious N Event designated
serious
N
Abdominal pain 5 Abdominal pain 2
With pneumoperitoneum
(including post-operative
anaesthetic-related
hypotension)
3
(1)
With abdominal
distension and
flatulence
1
Bowel obstruction 1 Post-operative peritonitis
and bowel perforation
1
Port-site haematoma 1 Post-operative
anaesthetic-related
hypotension
1
Clinically confirmed missed
miscarriage
1 Wound infection and
vomiting
2
Leg pain 1 With faecal impaction 1
Thrombosis 1
Intra-operative bleeding 1
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pneumoperitoneum as a covariate, there is mounting evidence that its
environment is also an important adhesiogenic factor.
The published efficacy of Adept in reducing adhesion reformation,
including in patients with a high adhesion burden and in difficult clinical
cases such as patients with inflammatory endometriosis, pain, infertility
and combinations thereof, are not challenged by this study as it only
focused on de novo adhesion formation (Brown et al., 2007). There
is good data to support continued use of Adept for reduction of
reformed adhesions. In relation to prevention of de novo adhesions fol-
lowing primary laparoscopic myomectomy, it seems apparent that sur-
geons need to carefully consider the size and number of myomas and
incision length when deciding whether open or laparoscopic surgery is
the better option.
For future research, the study allows us to recommend the need to
take careful steps to ensure as homologous a study population as
possible. This may include limiting the number of centres, the
surgery types and ensure they are narrowly defined to minimize
intra- and inter-centre surgery variables and improve study sensitivity.
Focusing on a single-patient population will further assist.
Although Adept as a fluid agent works throughout the abdomino-
pelvic cavity, for the purposes of future research with this agent, focus-
ing on site-specific changes rather than simply a global effect is likely to
provide more important data on clinical efficacy. In GENEVA, while a
global reduction in de novo adhesions was not seen with Adept com-
pared with LRS, it was found that the severity and extent of adhesions
to the posterior uterus was lower in the Adept group. While indepen-
dent video reviews throughout the abdominopelvic cavity enhance the
robust nature of research, for future studies it may be also valuable to
have access to surgeon readings to identify anomalies/issues with
video reviews and further verify adhesion scorings.
Conclusion
The GENEVA study identified a very high incidence of de novo
adhesion formation even amongst centres specializing in laparoscopic
gynaecological surgery.
The study results provided further confirmation of the safety
aspects of Adept use. Although the study found no difference
between Adept and LRS in overall de novo adhesion formation,
scoring of the adhesion severity and extent, it provides direction for
future adhesion reduction strategies in site-specific surgery such as
myomectomy, where use of a site-specific barrier agent, perhaps in
conjunction with Adept, may be a better strategy to reduce adhesions.
Further research may be required to examine this.
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study. Members included I.F. (chair); G.T. (principal investigator);
G.D.; Christopher Sutton, Professor of Gynaecological Surgery, Uni-
versity of Surrey, UK; Per Lundorff, Viborg Hospital, Department of
Obstetrics and Gynaecology, Denmark. The primary remit of the
DSMB was to protect the interests of the study patients and
review all adverse event data and make recommendations, if appro-
priate, for any changes to the study protocol or, in the case of
significant concerns, recommendations for early termination of the
study. The DSMB also had the authority to stop the trial
because of overwhelming evidence of a difference between
treatments if the comparison between the rates of the primary
end-point achieved statistical significance (P, 0.001 in a two-sided
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statistical test) at a second unblinded interim analysis. The DSMB
functioned in accordance with a designated charter.
Other investigators
and sub-investigators
In addition to the named authors other study investigators included
Bernard Blanc, Marseille, France; Herve Dechaud, Montpelier,
France; Claude Hocke´, Bordeaux, France; Patrick Madelenat, Paris,
France; Mario Malzoni, Avellino, Italy and Luca Minelli, Negrar, Italy.
Sub-investigators involved in the study data acquisition at various
contributing centres included Dr Aubert Agostini, Hoˆpital de la Con-
ception, Marseille, France; Dr Julia Bockenheimer, Krankenhaus
Ko¨ln-Weyertal GmbH, Ko¨ln, Germany; Dr Jean-Luc Brun, Hopital
Pellegrin, Bordeaux, France; Dr Eduard Elek, Klinikum Duisburg,
(Wedau Kliniken), Duisburg, Germany; Dr Herve´ Foulot, Clinique
Universitaire Baudeloque, Paris France; Dr Petra Janssen, Klinikum
Konstanz, Konstanz, Germany; Dr Stefano Landi, Ospedale Sacro
Cuore, Negrar Verona, Italy; Dr Xenia Lechat, Hoˆpital Saint Andre´,
Bordeaux, France; Dr Juergen Mewald, Universita¨ts-Frauenklinik
Tu¨bingen, Tu¨bingen, Germany; Dr Konstantinos Myrillas, AKESO,
Gynaecology and Reproductive Centre, Athens, Greece; Dr Sophie
Omnes, Hoˆpital Bichat, Paris, France; Dr Massimiliano Pellicano,
Universita` degli studi di Napoli Federico II, Naples, Italy; Dr Francesca
Rizzello, Florence, Italy; Dr Lorenzo Rozza, Casa di Cura Malzoni ‘Villa
dei Platani’, Avellino, Italy; Dr Erich Solomayer, Universita¨ts-
Frauenklinik Tu¨bingen, Tu¨bingen, Germany.
Contract research organization
PAREXEL International, Uxbridge, Middlesex, UK were the CRO
appointed by Shire to coordinate and monitor the study and
manage data entry. Their sister organization, Perceptive Informatics,
Inc., Berlin Germany was appointed by Shire to manage the
independent video reviews.
Appendix 2
Video recording
Systematic review of eight key organ sites: right paracolic gutter and
right large bowel (intestinum crassum); cephalad anterior peritoneum
right then left; left paracolic gutter and left large bowel; rectosigmoid;
omentum and small bowel (intestinum tenue).
Video recording of 23 mAFS adhesion sites
......................................................................................
Anatomical site Description
Cephalad anterior
peritoneum—right
Cephalad of uterine fundus and right of
midline
Caudal anterior
peritoneum
Caudal with respect to fundus of uterus
including bladder flap
Right large bowel Large bowel (intestinum crassum) right of
midline
Cephalad anterior
peritoneum—left
Cephalad of uterine fundus and left of midline
Left large bowel Large bowel (intestinum crassum) left of
midline
Rectosigmoid Portion of sigmoid colon in the pelvis
Omentum
Small bowel Intestinum tenue
Anterior uterus Uterine surface anterior to tubal insertion
(cornual plane)
Posterior uterus Uterine surface posterior to tubal insertion
(cornual plane)
Cul-de-sac
(posterior)
Posterior cul-de-sac medial to the uterosacral
ligaments
Medial ovary—right
and left side
Most medial portion of the anterior surface of
ovary (one-half of the anterior surface closest
to the lateral aspect of the uterus)
Lateral ovary—right
and left side
Most lateral portion of the anterior surface of
ovary (one-half of the anterior surface farthest
from the lateral aspect of the uterus)
Sidewall—right and
left side
Lateral aspect to the uterosacral ligament
Ovarian fossa—right
and left side
That portion of the ovary (all of the posterior
surface) which is in contact with the broad
ligament
Tube—right and left
side
Aspect of the fallopian tube proximal to the
ampulla (includes isthmus and cornua)
Ampulla—right and
left side
Includes the fallopian tube infundibulum and
fimbriae
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